Formerly thought as an effector enzyme of the immune system debarring pathogen bacteria from the essential amino acid l-Trp, IDO1 has experienced a new lease of life with seminal discoveries about its involvements in mediating maternal immune tolerance and the tumor immuno-editing process. Here, IDO1 is linked to neoplasm.